{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"MediWound Ltd."},"Symbol":{"label":"Symbol","value":"MDWD"},"Address":{"label":"Address","value":"42 HAYARKON STREET, YAVNE, 8122745, Israel"},"Phone":{"label":"Phone","value":"+972 779714100"},"Industry":{"label":"Industry","value":" Medicinal Chemicals and Botanical Products "},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Middle East"},"CompanyDescription":{"label":"Company Description","value":"MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. Its first biopharmaceutical product, NexoBrid removes dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns also referred to as severe burns. NexoBrid is currently in clinical development in North America and is in the process of preparing its Biologics License Application. The company derives its revenue from the United States."},"CompanyUrl":{"label":"Company Url","value":"https://www.mediwound.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Asi Haviv","title":"Medical Director"},{"name":"Eilon Asculai","title":"Vice President-Research & Development"},{"name":"Ety Klinger","title":"Chief Research & Development Officer"},{"name":"Keren David-Zarbiv","title":"Vice President-Clinical Affairs"},{"name":"Ofer Gonen","title":"Chief Executive Officer"},{"name":"Robert J. Snyder","title":"Chief Medical Officer"},{"name":"Shmulik Hess","title":"Chief Operating & Commercial Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}